Acute 'strokenomics': Efficacy and economic analyses of alteplase for acute ischemic stroke

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 9, Issue 6, 2009, Pages 513-522

  Quinn, Terence J ^a   Dawson, Jesse ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Alteplase; Cerebrovascular accident; Clinical trial; Cost effectiveness; Economics; Thrombolytic therapy; Tissue plasminogen activator

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; CANADA; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG UTILIZATION; ECONOMIC ASPECT; ECONOMIC EVALUATION; EUROPE; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; FOLLOW UP; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; LICENSING; LONG TERM CARE; MEDICAL CARE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATIENT SELECTION; PHYSICAL DISABILITY; RECOMMENDED DRUG DOSE; REHABILITATION CARE; REVIEW; RISK REDUCTION; SOCIAL CARE; UNITED STATES;

ADULT; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FIBRINOLYTIC AGENTS; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 73549110269     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.09.63     Document Type: Review

References (76)

1. Seshadri S, Beiser A, Kelly-Hayes M et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke 37(2), 345-350 (2006).
2. Rich DQ, Gaziano JM, Kurth T Geographic patterns in overall and specific cardiovascular disease incidence in apparently healthy men in the United States. Stroke 38(8), 2221-2227 (2007).
3. Hallstrom B, Jonsson AC, Nerbrand C, Norrving B, Lindgren A. Stroke incidence and survival in the beginning of the 21st Century in southern Sweden: comparisons with the late 20th Century and projections into the future. Stroke 39(1), 10-15 (2008).
4. Durai PJ, Padma V, Vijaya P, Sylaja PN, Murthy JM. Stroke and thrombolysis in developing countries. Int. J. Stroke 2(1), 17-26 (2007).
5. Dawson J, Lees JS, Chang TP et al. Association between disability measures and healthcare costs after initial treatment for acute stroke. Stroke 38(6), 1893-1898 (2007).
6. Schmulling S, Grond M, Rudolf J, Heiss WD. One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke 31(7), 1552-1554 (2000).
7. Dhamoon MS, Moon YP, Paik MC et al. Long-term functional recovery after first ischemic stroke: the Northern Manhattan Study. Stroke 40(8), 2805-2811 (2009).
8. Qureshi AI, Suri MF, Nasar A et al. Changes in cost and outcome among US patients with stroke hospitalized in 1990 to 1991 and those hospitalized in 2000 to 2001. Stroke 38(7), 2180-2184 (2007).
9. Luengo-Fernandez R, Gray AM, Rothwell PM. Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom. Stroke 37(10), 2579-2587 (2006).
10. Luengo-Fernandez R, Gray AM, Rothwell PM. Costs of stroke using patient-level data: a critical review of the literature. Stroke 40(2), e18-e23 (2009).
11. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke 36(11), 2500-2503 (2005).
12. Grieve R, Hutton J, Bhalla A et al. A comparison of the costs and survival of hospital-admitted stroke patients across Europe. Stroke 32(7), 1684-1691 (2001).
13. Naess H, Waje-Andreassen U, Thomassen L, Nyland H, Myhr KM. Health-related quality of life among young adults with ischemic stroke on long-term follow-up. Stroke 37(5), 1232-1236 (2006).
14. Earnshaw SR, Jackson D, Farkouh R, Schwamm L. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis. Stroke 40(5), 1710-1720 (2009).
15. Saver JL. Time is brain - quantified. Stroke 37(1), 263-266 (2006).
16. Lees KR. ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II. Lancet 353(9146), 65-66 (1999).
17. Fagan SC, Morgenstern LB, Petitta A et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 50(4), 883-890 (1998).
18. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282(21), 2019-2026 (1999).
19. Quinn TJ, Dawson J, Lees KR. Past, present and future of alteplase for acute ischemic stroke. Expert Rev. Neurotherapeutics 8, 181-192 (2008).
20. Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363(9411), 768-774 (2004).
21. Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359(13), 1317-1329 (2008).
22. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch. Neurol. 61(7), 1066-1070 (2004).
23. Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke 38(8), 2279-2283 (2007).
24. IST Investigators. The International Stroke Trial (IST), a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 349(9065), 1569-1581 (1997).
25. Langhorne P, Williams BO, Gilchrist W, Dennis MS, Slattery J. A formal overview of stroke unit trials. Rev. Neurol. 23(120), 394-398 (1995).
26. Langhorne P. The role of stroke units. Ir. Med. J. 88(5), 150 (1995).
27. Gilligan AK, Thrift AG, Sturm JW, Dewey HM, Macdonell RA, Donnan GA. Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit? Cerebrovasc. Dis. 20(4), 239-244 (2005).
28. Moodie ML, Carter R, Mihalopoulos C et al. Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke. Stroke 35(5), 1041-1046 (2004).
29. Wahlgren N, Ahmed N, Davalos A et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST), an observational study. Lancet 369(9558), 275-282 (2007).
30. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283(9), 1145-1150 (2000).
31. Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J. Neurol. Neurosurg. Psychiatry 77(7), 826-829 (2006).
32. Adams HP Jr, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38(5), 1655-1711 (2007).
33. Chung H, Refoios CR, Barnett D. Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance. Heart 93(12), 1616-1617 (2007).
34. Alvarez-Sabin J, Molina CA, Montaner J et al. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator - treated patients. Stroke 34(5), 1235-1241 (2003).
35. Yong M, Kaste M. Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial. Stroke 39(2), 366-372 (2008).
36. Sare GM, Ali M, Shuaib A, Bath PM. Relationship between hyperacute blood pressure and outcome after ischemic stroke: data from the VISTA collaboration. Stroke 40(6), 2098-2103 (2009).
37. Rudd AG, Hoffman A, Irwin P, Lowe D, Pearson MG. Stroke unit care and outcome: results from the 2001 National Sentinel Audit of Stroke (England, Wales, and Northern Ireland). Stroke 36(1), 103-106 (2005).
38. Horowitz SH. Thrombolytic therapy in acute stroke: neurologists, get off your hands! Arch. Neurol. 55(2), 155-157 (1998).
39. Innes K. Thrombolysis for acute ischaemic stroke: core nursing requirements. Br. J. Nurs. 12(7), 416-424 (2003).
40. Wardlaw JM, Seymour J, Cairns J, Keir S, Lewis S, Sandercock P. Immediate computed tomography scanning of acute stroke is cost-effective and improves quality of life. Stroke 35(11), 2477-2483 (2004).
41. Bornstein NM. Dedicated stroke units and outcome. Isr. Med. Assoc. J. 7(11), 739 (2005).
42. Kwan J, Hand P, Sandercock P. Improving the efficiency of delivery of thrombolysis for acute stroke: a systematic review. QJM 97(5), 273-279 (2004).
43. Kwan J, Hand P, Sandercock P. A systematic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing 33(2), 116-121 (2004).
44. Juttler E, Schwab S, Schmiedek P et al. Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY), a randomized, controlled trial. Stroke 38(9), 2518-2525 (2007).
45. Sandercock P, Berge E, Dennis M et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 35(6), 1490-1497 (2004).
46. Sinclair SE, Frighetto L, Loewen PS et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 19(9), 927-936 (2001).
47. Chambers M, Koch P, Hutton J. Development of a decision analytical model of stroke care in United States and Europe. Value Health 5, 85-97 (2002).
48. Samsa GP, Reutter RA, Parmigiani G et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J. Clin. Epidemiol. 52(3), 259-271 (1999).
49. Yip TR, Demaerschalk BM. Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada. Stroke 38(6), 1952-1955 (2007).
50. Ehlers L, Muskens WM, Jensen LG, Kjolby M, Andersen G. National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine in Denmark: a model of budgetary impact and cost effectiveness. CNS Drugs 22(1), 73-81 (2008).
51. Ehlers L, Andersen G, Clausen LB, Bech M, Kjolby M. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 38(1), 85-89 (2007).
52. Mar J, Begiristain JM, Arrazola A. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc. Dis. 20(3), 193-200 (2005).
53. Nadareishvili Z, Oh P, Smurawska LT, Tran C, Norris JW Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 52(4), 895-896 (1999).
54. Scott PA, Silbergleit R. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke 37(4), 943-944 (2006).
55. Barradell LB, Goa KL. Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction. Pharmacoeconomics 8(5), 428-459 (1995).
56. Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst. Rev. 4, CD000213 (2009).
57. Grieve R, Hutton J, Bhalla A et al. A comparison of the costs and survival of hospital-admitted stroke patients across Europe. Stroke 32(7), 1684-1691 (2001).
58. Nadeau JO, Shi S, Fang J et al. TPA use for stroke in the Registry of the Canadian Stroke Network. Can. J. Neurol. Sci. 32(4), 433-439 (2005).
59. Kulkens S, Hacke W. Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies. Expert Rev. Neurother. 7(7), 783-788 (2007).
60. Ingall TJ, OTallon WM, Asplund K et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 35(10), 2418-2424 (2004).
61. Demaerschalk BM, Bobrow BJ, Paulsen M. Development of a metropolitan matrix of primary stroke centers: the Phoenix experience. Stroke 39(4), 1246-1253 (2008).
62. Hacke W, Albers G, Al Rawi Y et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS), a Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36(1), 66-73 (2005).
63. Edwards LL. Using tPA for acute stroke in a rural setting. Neurology 68(4), 292-294 (2007).
64. Scott PA, Temovsky CJ, Lawrence K, Gudaitis E, Lowell MJ. Analysis of Canadian population with potential geographic access to intravenous thrombolysis for acute ischemic stroke. Stroke 29(11), 2304-2310 (1998).
65. Uren B, Lowell MJ, Silbergleit R. Critical care transport of patients who have acute neurological emergencies. Emerg. Med. Clin. North Am. 27(1), 17-26, VII (2009).
66. Audebert HJ, Kukla C, Clarmann VC et al. Telemedicine for safe and extended use of thrombolysis in stroke: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria. Stroke 36(2), 287-291 (2005).
67. Silliman SL, Quinn B, Huggett V, Merino JG. Use of a field-to-stroke center helicopter transport program to extend thrombolytic therapy to rural residents. Stroke 34(3), 729-733 (2003).
68. Silbergleit R, Scott PA, Lowell MJ, Silbergleit R. Cost-effectiveness of helicopter transport of stroke patients for thrombolysis. Acad. Emerg. Med. 10(9), 966-972 (2003).
69. Meseguer E, Labreuche J, Olivot JM et al. Determinants of outcome and safety of intravenous rt-PA therapy in the very old: a clinical registry study and systematic review. Age Ageing 37(1), 107-111 (2008).
70. Mateen FJ, Nasser M, Spencer BR et al. Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older. Mayo Clin. Proc. 84(4), 334-338 (2009).
71. Boode B, Welzen V, Franke C, van Oostenbrugge R. Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc. Dis. 23(4), 294-298 (2007).
72. Cocho D, Belvis R, Marti-Fabregas J et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 64(4), 719-720 (2005).
73. Walters MR, Muir KW, Harbison J, Lees KR, Ford GA. Intravenous thrombolysis for acute ischaemic stroke: preliminary experience with recombinant tissue plasminogen activator in the UK. Cerebrovasc. Dis. 20(6), 438-442 (2005).
74. 2 scores and prediction of noncerebrovascular diagnoses in an outpatient population: a case-control study. Stroke 40(3), 749-753 (2009).
75. Nguyen-Huynh MN, Johnston SC. Is hospitalization after TIA cost-effective on the basis of treatment with tPA? Neurology 65(11), 1799-1801 (2005).
76. University Hospital, University of Medicine and Dentistry, Newark, NJ, USA www.theuniversityhospital.com/stroke/stats.htm